


November 17-19, 2026 | Boston, MA
www.til-therapies.com

REGISTER BY
FRIDAY, AUGUST
28 TO SAVE UP
TO \$840



8th Annual

TIL Therapies Summit

Optimizing TIL to Expand Patient Reach in Melanoma, Lung & Beyond

Expand Patient Access in Solid Tumors With Next-Generation Gene Editing & Harmonized Potency & QC Frameworks to Scale Clinical Studies to Commercial Success

Expert Speakers Include:



Nicholas Restifo
Chief Medical Officer
Medici Therapeutics



Andrew Weinberg
President & Chief
Scientific Officer
AgonOx



Lucas Arruda
Chief Scientific
Officer
CuraCell Holding



Jonas Bätelson
Co-Founder & Chief
Executive Officer
CuraCell Holding



Karrie Wong
Vice President
KSQ Therapeutics



Parameswaran Hari
Chief Development
Officer
**Obsidian
Therapeutics**

Proud to Partner With:



a joint venture between Resilience
+ MD Anderson Cancer Center



+1 617 455 4188 @ info@hansonwade.com

www.til-therapies.com Cell & Gene Therapy Event Series



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the 8th TIL Therapies Summit

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

With the first FDA approval for TIL therapy achieved in 2024, the field has moved from proof of concept to clinical reality and in 2026, the priority is clear: prove TIL's full value as a transformative, one-and-done solid tumor therapy.

As investment pressure reshapes the cell therapy landscape, the **8th TIL Therapies Summit** returns to Boston as the industry's longest-standing, most hyper-focused forum dedicated exclusively to advancing TIL into safe, effective patient cures.

Uniting biotech, academia, and clinical leads, this end-to-end meeting drives progress on efficacy and safety, expanding melanoma access, and accelerating into new solid tumor indications.

Join your community in this intimate setting to discuss:

- Advancing patient selection** through predictive biomarkers, translational data, and biologically informed enrollment strategies to improve clinical outcomes
- Expanding TIL therapies beyond melanoma** by generating clinical evidence in colorectal, breast, prostate, cervical, and other emerging solid tumor indications
- Evaluating next-generation engineered and gene-edited TIL** approaches to enhance persistence, overcome tumor resistance, and widen patient eligibility
- Scaling and industrializing TIL manufacturing** through automation, digitalization, and process standardization to reduce cost, timelines, and manufacturing risk
- Understanding the clinical, operational, and commercial milestones** required to restore investor confidence and establish long-term success for TIL therapies

Key Benefits of Attending



Get Ahead on Next-Generation TIL Engineering & Selection Strategies

Learn how to boost tumor-antigen recognition, cut IL-2 toxicity, and select truly tumor-reactive clones, with approaches from **KSQ Therapeutics**, **Obsidian Therapeutics**, **AgonOx**, and **Medici Therapeutics**.



Benchmark Your Manufacturing Strategy Against Real Commercial-Scale Data

See what it actually takes to scale from early clinical manufacturing to commercial-ready supply. **Huasai Bio** and **NEOGAP Therapeutics** tackles balancing process flexibility with standardization as trials scale, and **Tigen Pharma** breaks down automated QC release testing and next-generation potency assays built to cut bottlenecks.



Pressure-Test Your Potency & QC Release Strategy Against Peer Approaches

Compare how peers are tackling residuals, impurities, and non-specific cytokine readouts while understanding the critical groundwork needed, with no single predictive potency assay yet established for TIL products.



Learn How Leading Programs Are Cracking Cold & Non-Melanoma Solid Tumors

Get a clear read on which biological and manufacturing approaches are translating beyond melanoma, from **Curacell's** clinical work in colorectal and prostate cancer to **Achelois Biopharma** and **Junecell's** manufacturing innovations for cold and unresectable tumors.



Connect Biomarker Science to Real Patient Selection Decisions

Turn biomarker data into a practical patient selection framework, with **Hospital Clínic Barcelona (IDIBAPS)** on predicting response and **Obsidian Therapeutics** on widening eligibility criteria.

Why Attendees Keep Coming Back

“Good presentations on the future of TIL therapy and its current application in clinical practice”

**Associate Director & Cell Therapy Account Manager
Iovance**

“Nice variety of presentations from companies, academic institutes, and clinical partners”

**Principal Scientist - Analytical Development
Obsidian Therapeutics**

“Being able to hear presentations from industry and academic leaders in the TIL therapy field and the opportunity to network with industry leaders for collaboration”

**Associate Professor
Ohio State**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



+1 617 455 4188

@ info@hansonwade.com

www.til-therapies.com

Cell & Gene Therapy Event Series



What's New For 2026?

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

Join leading developers to explore clinical expansion beyond melanoma, next-generation engineered TIL platforms, biomarker-driven patient selection, manufacturing innovation, and the strategies needed to deliver commercially successful TIL therapies to more patients.

New Companies include:



HUASAIBIO 华赛伯曼



Sessions You Won't Want to Miss:



Strengthening Solid Tumor Efficacy by Engineering TILs with Precision Genome Editing to Improve Recognition & Durability

As TIL therapies move beyond melanoma, learn how precision genome editing is being used to enhance tumor recognition, improve persistence, and drive more durable responses in solid tumors. Discover how engineered TILs could redefine the next generation of cell therapy.

Karrie Wong, Vice President - Research, **KSQ Therapeutics**

1



Engineering TIL to Address the Obstacles to Wider Patient Eligibility

Patient access remains one of the field's greatest challenges. Join Obsidian Therapeutics to explore innovative engineered TIL approaches designed to reduce treatment burden, improve safety, and enable more patients to benefit from TIL therapy.

Giridharan Ramsingh, Vice President, Clinical Science, **Obsidian Therapeutics**

2

How You Can *Infiltrate* The Summit:

Speed Networking & Networking Breaks

Over six hours dedicated to sparking new connections and strengthening that last well beyond the summit.

Interactive Workshops

Explore key challenges, share experiences, and gain practical insights from experts in a small group setting to make introductions with those working on the exact same issue.

Roundtables & Panels

Engage with peers on open and candid discussions on the latest challenges, innovations, and opportunities.

Poster Session

Showcase emerging research, new technologies and innovative approaches, and hear immediate feedback from fellow attendees, researchers, and potential collaborators.

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Expert Speakers

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

C-Suite Leaders



Eric Chen
Founder & Chief Executive
Officer
Achelois BioPharma



Andrew Weinberg
Chief Executive Officer
AgonOx



Lucas Arruda
Chief Scientific Officer
CuraCell Holding



Jonas Båtelson
Co-Founder & Chief
Executive Officer
CuraCell Holding



Pin Wang
Chief Scientific Officer
Grit Biotechnology



Zhang Changfeng
Chief Executive Officer
Huasai Biomedicine



Nicholas Restifo
Chief Medical Officer
Medici Therapeutics



Samuel Svensson
Chief Executive Officer
NEOGAP Therapeutics



Parameswaran Hari
Chief Development Officer
Obsidian Therapeutics



Therese Choquette
Chief Technical Officer
Tigen Pharma

Strategic Experts



Karrie Wong
Vice President
KSQ Therapeutics



Anne-Laure Joly
Cell Therapy Development
& Analyses, Scientific
Lead
NEOGAP Therapeutics



Giridharan Ramsingh
Vice President, Clinical
Science
Obsidian Therapeutics



Mengmeng Tang
Vice President
Juncell Therapeutics



Aaron Goldman
Operating Partner
Broad Oak Capital

Academic Pioneers



**Víctor Albarrán
Fernández**
Medical Oncologist &
Researcher, Cell Therapy
for Solid Tumors
**Hospital Clínic Barcelona
Comprehensive
Cancer Center (4CB) /
IDIBAPS**



Maximilian Julve
Clinical Assistant
Professor
Stanford University



Jessica Chacon
Associate Professor
**Texas Tech University
Health Sciences Center**



Eduardo Davila
Professor of Medical
Oncology
University of Colorado



Michael Lotze
Professor of Surgery,
Immunology
University of Pittsburgh

Pre-Conference Workshop Day

Tuesday | November 17, 2026

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Check In & Light Breakfast

9.00

Workshop A

9:30 - 12.30

Improving Patient Access to TIL Therapies by Coordinating Clinical Trial Operations to Enable Earlier Treatment & Broader Reach

Delivering TIL therapies at scale requires close collaboration between community physicians' specialist centers, surgeons and clinical trial teams rather than changes by any single group alone. As clinical evidence matures and trials expand into earlier lines and broader populations, the challenge is aligning referral timing, clinician education, hospital resources, and trial logistics. This workshop focuses on shared problem solving across clinical and operational roles to support access while maintaining high standards of care and trial integrity.

Key questions addressed in this workshop:

- How can referral pathways be strengthened through earlier collaboration with community oncologists and shared visibility of patient flow?
- What practical approaches help clinicians, surgeons, and trial teams align around beds surgery slots and manufacturing availability?
- How can education reimbursement considerations and trial participation work together to support treatment beyond specialist centers?
- How should clinical trials be designed to reflect real-world workflows while enabling access expansion and operational feasibility?

Workshop Leaders



Michael Lotze
Professor of Surgery, Immunology
University of Pittsburgh

Lunch & Networking

12.30

Workshop B

1.30 - 4.30

Trade-Offs Between Specificity, Potency, Scalability, & Safety in Current TIL Approaches

As the field moves beyond melanoma, the need for optimized efficacy and safety is forcing a rethink of manufacturing strategies and delivery strategies.

This workshop addresses the growing recognition that current TIL strategies involve bulk TIL expansion, diluting tumor reactive potential and requiring high dose IL-2 for efficacy.

Key questions addressed in this workshop:

- Which tumor-infiltrating lymphocyte subsets are truly reactive rather than expanded bystanders?
- Do selection approaches such as PD-1 or neoantigen targeting enrich potency or accelerate exhaustion?
- How can next-generation approaches optimize safety vs. efficacy?

Workshop Leaders



Maximilian Julve
Clinical Assistant Professor
Stanford University



Andrew Weinberg
Chief Executive Officer
AgonOx



Jessica Chacon
Associate Professor
Texas Tech University Health Sciences Center



Lucas Arruda
Chief Scientific Officer
CuraCell Holding

End of Preconference Workshop Day

4.30



+1 617 455 4188 @ info@hansonwade.com

www.til-therapies.com in Cell & Gene Therapy Event Series



Conference Day One

Wednesday | November 18, 2026

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Registration & Light Breakfast



Michael Lotze
Professor of
Surgery,
Immunology
**University of
Pittsburgh**

8.50 Chair's Opening Remarks

Showcasing Clinical Evidence Across Melanoma & Emerging Solid Tumor Indication to Inform Where TILs Can Deliver Meaningful Benefit to Patients

9.00 Advancing TIL Clinical Development by Generating Early Efficacy Signals in Cold Solid Tumors



Lucas Arruda
Chief Scientific Officer
CuraCell Holding

- Demonstrating initial clinical feasibility of TIL therapy in colorectal and prostate cancer
- Exploring patient selection and tumor sourcing challenges in low immunogenic indications
- Translating early treatment experience into future trial design decisions

9.30 Advancing TIL Therapy in Advanced Melanoma With Clinical Evidence Supporting a Next Generation Treatment Approach



Mengmeng Tang
Vice President
Juncell Therapeutics

- Presenting pivotal clinical data from patients with advanced melanoma, demonstrating achievement of the study's primary endpoint and supporting the potential for the first marketed TIL therapy in China
- Exploring innovations in treatment delivery through an IL-2-free regimen, low-intensity pretreatment, and a feeder-free manufacturing process designed to simplify therapy while maintaining clinical efficacy
- Examining outcomes in predominantly acral and mucosal melanoma populations and discussing what these findings could mean for the future evolution of TIL therapy



10:00 Morning Break & Speed Networking

Join our dedicated networking session to engage in dynamic, fast-paced conversations with fellow industry professionals, exchange insights and expertise, and expand your network within the rapidly evolving TIL therapies landscape. This interactive session will help you foster impactful partnerships and advance innovation across the field.

Engineering Better TIL Products Through Targeted Tumor-Reactive Cell Selection

11.00 Expanding TIL Clinical Activity Beyond Melanoma by Selectively Enriching Tumor Reactive T-cells



Andrew Weinberg
Chief Executive Officer
AgonOx

- Demonstrating clinical feasibility of isolating tumor reactive T-cells across multiple solid tumor types
- Sharing early phase safety and response observations from a selective TIL approach
- Informing future trial design by linking cell composition to clinical outcomes



Miltenyi Biotec

11:30 Session Reserved for Miltenyi Biotech

12.00 Advancing TIL Therapy Through Neoantigen-Guided Selection of Tumor-Reactive T-Cells



Nicholas Restifo
Chief Medical Officer
Medici Therapeutics

- Leveraging patient-specific neoantigens to identify and enrich functional tumor-reactive T-cells
- Overcoming low frequencies of tumor-reactive lymphocytes in non-melanoma solid tumors
- Establishing a framework for next-generation, precision TIL manufacturing



12.30 Lunch & Networking



+1 617 455 4188

@ info@hansonwade.com

www.til-therapies.com

Cell & Gene Therapy Event Series



Conference Day One

Wednesday | November 18, 2026

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Advancing Gene-Edited TIL Therapies to Enhance Persistence, Overcome Tumor Resistance & Drive More Durable Clinical Responses



Karrie Wong
Vice President,
Research
KSQ Therapeutics

1.30 Strengthening Solid Tumor Efficacy by Engineering TILs With Precision Genome Editing to Improve Recognition & Durability

- Integrating targeted genetic edits to enhance tumor-specific antigen recognition
- Reducing functional exhaustion to support sustained TIL persistence after infusion
- Evaluating how multiplex engineering impacts response durability in solid tumors



2.00 Session Reserved for ScaleReady

2:30 Panel Discussion: Reducing Development Risk by Evaluating Genetic Editing Strategies Shaping the Future of TIL Therapies


- Comparing genome editing approaches used to enhance potency, persistence, and tumor recognition
- Reviewing safety, manufacturability, and regulatory trade-offs of engineered TIL designs
- Identifying where genetic modification adds clear clinical value vs. added complexity
- Can TIL manufacturing be designed for *in vivo* development rather than culturing the cells *in vitro*?




Pin Wang
Chief Scientific Officer
Grit Biotechnology



Andrew Weinberg
Chief Executive Officer
AgonOx



Jessica Chacon
Associate Professor
Texas Tech University



Eduardo Davila
Professor of Medical
Oncology
University of Colorado



11:45 Session Reserved for CTMC - a Joint Venture Between Resilience + MD Anderson Cancer Center



3.30 Afternoon Break & Poster Session

Contribute to the conversation by sharing your latest research and innovations with the global cell therapy community and leading experts advancing the future of TIL therapies.

Managing Scientific & Process Complexity to Improve Reliability & Decision Making in TIL Manufacturing

4.30 Building Robust Manufacturing & Quality Systems to Enable the Commercialization of TIL Therapies

- Establishing CMC quality systems that support consistent TIL manufacturing from early development through commercialization
- Exploring lessons learned from scaling autologous cell therapies from research to industrial manufacturing while maintaining product quality and regulatory compliance
- Navigating global regulatory expectations and integrating manufacturing, quality, and clinical development strategies to accelerate TIL therapy approval and commercialization



Zhang Changfeng
Chief Executive Officer
Hangzhou Husai Biomedicine



+1 617 455 4188

@ info@hansonwade.com

www.til-therapies.com

Cell & Gene Therapy Event Series



Conference Day One

Wednesday | November 18, 2026

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Anne-Laure Joly
Scientific Lead Cell
Therapy Development
& Analysis
**NEOGAP
Therapeutics**

5.00 Balancing Process Flexibility & Standardization While Preserving Antigen Specificity

- Optimizing manufacturing processes to increase cell dose and scalability while maintaining antigen specificity, functionality, and product quality throughout clinical development
- Ensuring product comparability as manufacturing processes evolve from early clinical studies to larger trials without compromising the biological characteristics that drive therapeutic activity
- Reducing regulatory and scale-up risk by establishing robust, reproducible manufacturing strategies that support both clinical expansion and future commercial readiness



Michael Lotze
Professor of
Surgery,
Immunology
**University of
Pittsburgh**

5.30 Chairs' Closing Remarks

5.30 End of Conference Day One

“An outstanding panel of presenters discussing highly pertinent basic, translational and clinical aspects of TIL therapies. This is one of the best meetings I have had a pleasure to attend”

Director, Cellular Immunotherapy Laboratory, **Columbia University**

Conference Day Two

Thursday | November 19, 2026

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Registration & Light Breakfast



Michael Lotze
Professor of
Surgery,
Immunology
**University of
Pittsburgh**

8.50 Chair's Opening Remarks

Reducing Quality Control & Potency Assay Bottlenecks to Enable Timely Product Release

9.00 Accelerating TIL Manufacturing Through Automated QC Release Testing & Next-Generation Potency Assays



Therese Choquette
Chief Technical Officer
Tigen Pharma

- Sharing strategies to accelerate product release through automated quality control workflows, rapid sterility testing, and conditional release approaches to reduce manufacturing bottlenecks
- Exploring how automation can improve consistency, scalability, and efficiency across TIL manufacturing while maintaining product quality and regulatory compliance
- Discussing current challenges in developing meaningful potency assays for TIL products and evaluating emerging approaches to better characterize product function and predict clinical performance

9.30 Roundtable Discussion: Advancing the Field by Confronting Potency & QC Bottlenecks to Reduce Delays Across Development

- Comparing how different organizations experience potency and release testing challenges
- Discussing how regulators view necessary but non-predictive assays
- Exploring whether greater alignment could shorten timelines for the wider field



10.15 Morning Break & Networking

Leveraging Predictive Biomarkers & Prognostic Signatures to Refine Patient Selection & Enable More Consistent Clinical Responses in TIL Therapies



**Víctor Albarrán
Fernández**
Medical Oncologist
& Researcher, Cell
Therapy for Solid
Tumors
**Hospital Clínic
Barcelona
Comprehensive
Cancer Center (4CB) /
IDIBAPS**

11.15 Advancing Clinical Decision Making by Reverse Translating Tumor & T-Cell Biomarker Signals Into Actionable TIL Response Frameworks

- Leveraging PD-1-positive TIL selection strategies as surrogate biomarkers of tumor reactivity in breast cancer solid tumor
- Correlating TCR clonal expansion dynamics with multiomic translational datasets to identify predictive biomarkers of response
- Building translational workflows to integrate TCR sequencing, tumor biology, and patient response data for next-generation TIL and TCR-T development



Eric Chen
Founder & Chief
Executive Officer
Achelois Biopharma

11.45 Expanding the Reach of TIL Therapy: Reprogramming Patient Tumor Cells to Generate Potent Antigen-Specific T-Cells for Advanced & Cold Solid Tumors

- Reprogramming autologous tumor cells into antigen-presenting tumor cells (APTCs) to enable patient-specific antigen presentation without target selection
- Generating polyclonal antigen-specific T cells from peripheral blood to address unresectable and cold solid tumors
- Engineering tumor-specific T cells with intrinsic T-cell modifiers to enhance persistence and overcome tumor-mediated immunosuppression



+1 617 455 4188

@ info@hansonwade.com

www.til-therapies.com

Cell & Gene Therapy Event Series



Conference Day Two

Thursday | November 19, 2026

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Giridharan Ramsingh
Vice President, Clinical
Science
**Obsidian
Therapeutics**

12.15 Engineering TIL to Address the Obstacles to Wider Patient Eligibility

- Optimizing manufacturing to enable tumor tissue procurement by core needle biopsy and improve TIL functionality
- Applying membrane-bound IL15 expression to enable a low-dose lymphodepletion regimen
- Removing IL2-related toxicities using localized, regulatable, membrane-bound cytokine delivery
- Evaluating early safety and efficacy signals from engineered TIL in melanoma



12.45 Lunch & Networking

De-Risking First-in-Class TIL Therapies Through Regulatory Alignment & Commercial Validation to Secure Investment & Long-Term Success



Parameswaran Hari
Chief Development
Officer
**Obsidian
Therapeutics**

1.45 Advancing First-in-Class TIL Programs Through Uncertain Regulatory & Quality Expectations for Successful Approvals

- Navigating first time interactions with inexperienced review teams
- Defining and defending potency assays for complex cell products
- Applying quality by design concepts to highly variable therapies

2.15 Q&A & Panel Discussion: Evaluating TIL Programs Through an Investor Lens to Drive Sustainable Growth

- Examining how TIL leaders are balancing clinical efficacy, manufacturing complexity, and capital efficiency as investors become increasingly selective following capital-intensive cell therapy experiences
- Discussing the strategic decisions CEOs face when prioritizing indications, advancing next-generation platforms, pursuing partnerships, and managing development risk in a constrained funding environment
- Identifying the clinical, operational, and commercial milestones that most effectively rebuild investor confidence, support sustainable financing, and create long-term enterprise value



Samuel Svensson
Chief Executive Officer
NEOGAP Therapeutics



Jonas Båtelson
Chief Executive Officer & Co-Founder
CuraCell Holding



Aaron Goldman
Operating Partner
Broad Oak Capital



Michael Lotze
Professor of
Surgery,
Immunology
**University of
Pittsburgh**

3.15 Chairs' Closing Remarks

3.20 Close of the 8th TIL Therapies Summit

Great small conference with many very willing to share their struggles and solutions, unlike other occasions where information is too vague and uninformative. Great networking opportunities as well

Senior Scientist, Turnstone Biologics



Miltenyi Biotec

Expertise Partner

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative technologies enable solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 4,000 employees in 28 countries.

www.miltenyi.com



Expertise Partner

ScaleReady advances cell and gene therapy manufacturing through expertise, collaboration, and community. Working alongside therapy developers, ScaleReady helps teams simplify, standardize, and optimize their unique manufacturing processes around G-Rex® bioreactor technology and R&D Systems™ reagents. As a connector and collaborator across the CGT ecosystem, ScaleReady brings organizations together to exchange ideas, address shared challenges, and accelerate the development of therapies from early research through commercialization.

www.scaleready.com



Event Partner

Made Scientific is a leading US-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical- and commercial-supply. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the agility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.

www.madescientific.com



Event Partner

Scinus Cell Expansion Netherlands B.V. (Scinus) is an established partner in cell therapy and regenerative medicine, with a strong track record in translating cell culture processes into robust, GMP-compliant manufacturing workflows. Our Osilaris™ platform is a closed, GMP-ready bioreactor system designed for real-world production needs. As one of the most versatile bioreactor platforms, Osilaris™ supports adherent cells, suspension cells, and organoids in a single reactor. Its patented, single-use, volume-expandable culture bags enable high scale in a single run with a homogenized, ultra-low-shear environment. Osilaris™ also provides real-time monitoring and remote access for DO/pH control within a compliant GMP workflow, so you can run, monitor, and optimize cultures from anywhere with confidence.

www.scinus.com

Get Involved



Tazeen Kapadia

Partnerships Director

Tel: +1 (617) 455-4188

Email: sponsor@hansonwade.com



Expertise Partner

CTMC is a co-development accelerator formed by Resilience and MD Anderson Cancer Center to fast-track the development and manufacturing of next-generation cell therapies for cancer. Located in the heart of the Texas Medical Center, CTMC combines deep expertise in TIL and CAR-T platforms with integrated manufacturing and regulatory capabilities to accelerate the path from discovery to IND. As a true partner, we work side-by-side with cell therapy innovators, advancing programs into the clinic faster and charting a clear course to commercial readiness. Follow us on LinkedIn @ctmcplus to learn more.

www.ctmc.com

“The quality of the speakers and the attendees at the TIL conference is impressive. It is a great event to network with the top players in the field to share learnings and make connections.”

G-Rex Optimization Specialist
ScaleReady

Get Involved



Tazeen Kapadia
Partnerships Director
Tel: +1 (617) 455-4188
Email: sponsor@hansonwade.com

Partner With Us

8th Annual
TIL Therapies Summit
November 17-19, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Global Platform to Support to the Progress & Scale Out of TIL Therapies

The **8th TIL Therapies Summit** returns as the dedicated forum uniting the industry's leading developers looking to expand beyond their melanoma roots into larger patient populations and new solid tumor indications at scale.

From optimizing manufacturing workflows and increasing operational capacity to overcoming the complexities of pivotal trials and future commercialization, join the community driving the next chapter of TIL therapy development and accelerating patient access worldwide. *Can you afford not to be represented?*

Our audience is looking for support from the following types of partners:



CRO

Specialist clinical development support to accelerate trial execution, patient recruitment, regulatory strategy, and clinical success.



CDMO/ Manufacturing

Scalable manufacturing expertise and technologies to optimize TIL production, improve consistency, and enable commercial readiness.



Immune-Monitoring

Advanced assays and hard to heard analytical platforms to evaluate TIL function, persistence, patient response, and mechanisms of action.



Gene Engineering/ Gene Editing


Cell engineering solutions designed to enhance TIL potency, persistence, tumor targeting, and resistance to the tumor microenvironment.




Blood Banks

Access to high-quality donor material to support TIL research, process development, and translational studies.

Seniority of Attendees:*



Type of Companies Attending:*



Statistics Taken from 7th TIL Therapies Summit

Get Involved



Tazeen Kapadia
Partnerships Director
Tel: +1 (617) 455-4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



www.til-therapies.com/take-part/register



Tel: +1 617 455 4188



Email: info@hansonwade.com



Uncover exclusive insights from clinical and manufacturing leaders with real-world case studies on clinical outcomes, manufacturing scalability, and regulatory progress.



Develop your network across the TIL ecosystem with technical experts, clinicians, regulators, and biopharma leaders to exchange ideas, explore partnerships, and stay ahead of the curve in TIL innovation.



Implement actionable strategies to overcome key hurdles in TIL development, from cell expansion to patient selection and streamlined manufacturing, so you can drive meaningful progress in your own work.

Drug Developers	Register by Friday, August 28	On the Door Price
Conference + 2 Workshops	\$3,557 (Save \$840)	\$4,397
Conference + 1 Workshop	\$3,118 (Save \$630)	\$3,748
Conference Only	\$2,679 (Save \$420)	\$3,099

Academic & Research Institutes**	Register by Friday, August 28	On the Door Price
Conference + 2 Workshops	\$2,957 (Save \$840)	\$3,797
Conference + 1 Workshop	\$2,618 (Save \$630)	\$3,248
Conference Only	\$2,279 (Save \$420)	\$2,699

Service Providers	Register by Friday, August 28	On the Door Price
Conference + 2 Workshops	\$4,457 (Save \$840)	\$5,297
Conference + 1 Workshop	\$3,918 (Save \$630)	\$4,548
Conference Only	\$3,379 (Save \$420)	\$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com
Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic.
Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Hyatt Regency Boston Harbor
101 Harborside Dr, Boston, MA 02128

www.hyatt.com/hyatt-regency/en-US/bosha-hyatt-regency-boston-harbor

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event program as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



+1 617 455 4188



info@hansonwade.com



www.til-therapies.com



Cell & Gene Therapy Event Series



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE